Allakos Earnings Reports

Allakos reported a net loss of $18.4 million for the third quarter of 2024, with cash, cash equivalents, and investments totaling $92.7 million. Research and development expenses were $10.9 million, and general and administrative expenses were $8.9 million.

Allakos reported a net loss of $26.7 million for the second quarter of 2024. The company ended the quarter with $123.1 million in cash, cash equivalents and investments.

Allakos reported a net loss of $71.1 million for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $139.3 million, reflecting a decrease of $31.5 million during the quarter. Research and development expenses were $34.8 million, while general and administrative expenses amounted to $10.9 million.

Allakos reported a net loss of $62.6 million for the fourth quarter of 2023. The company halted lirentelimab-related development to focus on AK006 clinical development.

Allakos reported a net loss of $45.6 million for the third quarter of 2023, compared to a net loss of $30.8 million for the third quarter of 2022. Research and development expenses were $36.7 million, an increase of $18.3 million compared to the same period in 2022. The company ended the quarter with $193.9 million in cash, cash equivalents and investments.

Allakos reported a net loss of $35.1 million in the second quarter of 2023, compared to a net loss of $49.1 million in the second quarter of 2022. The company's cash, cash equivalents, and investments totaled $221.1 million at the end of the quarter.

Allakos reported a net loss of $42.4 million in the first quarter of 2023, compared to a net loss of $197.0 million for the same period in 2022. Research and development expenses were $33.1 million, significantly lower than the $176.8 million reported in the first quarter of 2022 due to cost reduction efforts. The company ended the quarter with $252.6 million in cash, cash equivalents and investments.

Allakos reported a net loss of $43.0 million for the fourth quarter of 2022, compared to a net loss of $94.4 million for the same period in 2021. The company's research and development expenses decreased significantly due to cost-cutting efforts.

Allakos reported a net loss of $30.8 million for the third quarter of 2022, compared to a net loss of $62.7 million for the same period in 2021. The company's research and development expenses were $18.4 million, including a $12.2 million benefit from raw material disposals, and general and administrative expenses were $13.0 million.

Allakos reported a net loss of $49.1 million in the second quarter of 2022, compared to a net loss of $57.2 million in the second quarter of 2021. The company's research and development expenses were $34.4 million, and general and administrative expenses were $14.7 million.

Allakos reported a net loss of $197.0 million in the first quarter of 2022, compared to a net loss of $55.6 million in the same period in 2021. The increased loss was primarily due to settlement costs related to exiting contractual obligations and workforce reduction.

Allakos reported a net loss of $94.4 million in the fourth quarter of 2021, compared to a net loss of $44.3 million in the same period in 2020. The company ended the quarter with $424.2 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $62.7 million in the third quarter of 2021, compared to a net loss of $42.1 million in the same period in 2020. The company ended the quarter with $505.6 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $57.2 million for the second quarter of 2021, compared to $39.3 million in the same period in 2020. The company ended the quarter with $559.7 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $55.6 million in the first quarter of 2021, compared to $27.8 million in the same period in 2020. The company ended the quarter with $615.9 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $44.3 million in the fourth quarter of 2020, compared to a net loss of $24.6 million in the same period in 2019. The company ended the year with $659.0 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $42.1 million in the third quarter of 2020, compared to $21.7 million in the same period in 2019. The company ended the quarter with $419.8 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $39.3 million in the second quarter of 2020, compared to $19.1 million in the same period in 2019. The company ended the quarter with $454.9 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $27.8 million in the first quarter of 2020, compared to $20.0 million in the same period in 2019. The company ended the quarter with $479.8 million in cash, cash equivalents and marketable securities.

Allakos reported a net loss of $24.6 million in the fourth quarter of 2019, compared to a net loss of $14.5 million in the same period in 2018. The company ended the year with $495.9 million in cash, cash equivalents and marketable securities.